Clinical Report: Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma

Overview

{'text': "This study evaluates the efficacy of immunoembolization (IE) in patients with liver-dominant metastatic uveal melanoma (mUM), revealing a disease control rate of 27.9% and a median overall survival of 32.7 months. Comparatively, IE shows shorter progression-free survival than melphalan via percutaneous hepatic perfusion but longer overall survival. Clarify the context of 'shorter' and 'longer' in relation to specific outcomes."}

Background

{'text': 'Uveal melanoma is the most common primary intraocular malignancy in adults, with a significant proportion developing liver metastases, which are associated with poor prognosis. Current treatment options for liver-dominant mUM are limited, including transarterial chemoembolization and systemic therapies, which have shown limited efficacy. Immunoembolization represents a novel approach combining localized immune stimulation with ischemic tumor control. Understanding the outcomes of IE is crucial for optimizing treatment strategies in this challenging patient population.'}

Data Highlights

Key Findings

• Overall DCR for IE was 27.9%, with complete response (CR) at 4.7% and partial response (PR) at 20.9%.
• Median PFS was 0.85 months, while median OS was 32.7 months.
• Patients with prior systemic therapy had improved outcomes, with median PFS of 29.9 months compared to 7.2 months for treatment-naïve patients.
• IE demonstrated a lower DCR compared to the FOCUS trial (27.9% vs. 73.6%) but a longer median OS (32.7 vs. 20.5 months).
• Choroidal primaries accounted for 95.3% of cases, and 90.7% had liver-only metastases.

Clinical Implications

{'text': 'Immunoembolization may serve as a viable liver-directed therapy for patients with liver-dominant mUM, particularly for those with prior systemic therapy. Clinicians should consider the potential sequencing of therapies, such as combining IE with systemic immunotherapy, to enhance patient outcomes.'}

Conclusion

{'text': 'The findings suggest that while immunoembolization has lower radiographic response rates compared to melphalan delivery, it offers comparable overall survival benefits, warranting further investigation in prospective trials. Future studies should focus on optimal sequencing strategies and combinations to improve therapeutic outcomes.'}

References

1. BJS (British Journal of Surgery), 2023 -- Approaches to Treating Liver Metastases Arising from Uveal Melanoma
2. The ASCO Post, 2026 -- Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
3. FDA, 2023 -- FDA approves melphalan as a liver-directed treatment for uveal melanoma
4. The ASCO Post — Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
5. The ASCO Post — Novel Drug/Device Combination May Improve Outcomes in Metastatic Uveal Melanoma
6. State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update
7. FDA approves melphalan as a liver-directed treatment for uveal melanoma | FDA
8. https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-1777712.pdf